Upcoming event

Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel by stratification factors in the phase 3 ARASENS Trial – Discusssant

2022-07-12

EAU22 game-chaning session webcast “Discussant: Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel by stratification factors in the phase 3 ARASENS Trial” by Dr. Radtke.

Watch the webcast of “Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel by stratification factors in the phase 3 ARASENS Trial” by Prof. Tombal here.

Tags: EAU22